Market Overview
The Cancer Screening and Precision Oncology Diagnostics Market covers the tests, platforms, laboratory services, imaging workflows, and molecular tools used to detect cancer early, classify tumors, select targeted therapy, monitor recurrence risk, and support treatment decisions across the oncology care pathway.The market includes colorectal cancer screening tests, mammography, cervical HPV testing, low-dose CT lung screening, prostate cancer testing, comprehensive genomic profiling, companion diagnostics, liquid biopsy, minimal residual disease testing, digital pathology, tumor-informed monitoring, and AI-supported pathology interpretation. It does not include cancer drugs, radiotherapy, surgery, general wellness testing, or imaging that is not used for screening or oncology diagnosis.
The global Cancer Screening and Precision Oncology Diagnostics Market was valued at USD 51,240 million in 2025 and is projected to reach USD 116,880 million by 2032, growing at a CAGR of 12.5% from 2026 to 2032.The reason this market is becoming strategically important is simple: oncology is moving from late diagnosis and broad treatment decisions toward earlier detection, biomarker-driven treatment selection, and long-term molecular monitoring. Global cancer burden data reinforces this need. IARC reported almost 20 million new cancer cases and close to 10 million cancer deaths in 2022, with annual new cancer cases projected to reach 35 million by 2050. Lung, breast, and colorectal cancer were among the most common cancers globally, while lung cancer remained the leading cause of cancer death.
What is driving the Cancer Screening and Precision Oncology Diagnostics Market?
The market is being driven by four practical shifts in cancer care: screening eligibility is expanding, non-invasive tests are making patient participation easier, companion diagnostics are becoming essential for therapy selection, and liquid biopsy is moving from advanced cancer profiling into recurrence monitoring and early detection.In the United States, colorectal cancer screening is recommended for adults aged 45 to 75, breast cancer screening now starts every other year at age 40 for women through age 74, and annual low-dose CT lung screening is recommended for high-risk adults aged 50 to 80 with a 20 pack-year smoking history who currently smoke or quit within the past 15 years. These recommendations create large recurring testing pools and give payers and providers a clearer basis for adoption.
A major market disruption is that cancer diagnostics are no longer one-time events. A patient may be screened, biopsied, sequenced, matched to therapy, monitored for molecular residual disease, and re-tested at progression. That creates a continuous diagnostic journey, not a single test transaction.
Cancer Screening and Precision Oncology Diagnostics Market Scope
| Metric | Value |
| Market size in 2025 | USD 51,240 million |
| Market size in 2032 | USD 116,880 million |
| CAGR, 2026 to 2032 | 12.5% |
| Largest product and technology type in 2025 | Cancer Screening Tests and Imaging-Based Screening |
| Fastest-growing product and technology type | Liquid Biopsy and MRD Testing |
| Largest cancer type in 2025 | Colorectal Cancer |
| Fastest-growing cancer type | Lung Cancer |
| Largest end user in 2025 | Hospitals and Cancer Centers |
| Fastest-growing end user | Home-Based and Decentralized Testing Channels |
| Largest region in 2025 | North America |
| Fastest strategic growth region | Asia-Pacific |
| Most important country market | USA |
| Key strategic trend | Convergence of early detection, genomic profiling, liquid biopsy, and recurrence monitoring |
Analyst Perspective
The Cancer Screening and Precision Oncology Diagnostics Market should be understood as an oncology decision infrastructure market, not just a testing market. The commercial value is not only in the test result. It is in the decision that follows: whether to screen again, perform colonoscopy, biopsy, sequence, prescribe targeted therapy, escalate treatment, de-escalate treatment, monitor recurrence, or enroll a patient in a clinical trial.This is why the strongest companies are not only selling assays. They are building access networks, payer evidence, regulatory credibility, clinician workflows, digital ordering systems, sample logistics, and data assets.
The under-discussed market shift is the move from “diagnostic accuracy” to diagnostic completion. A technically strong test has limited value if patients do not complete it, physicians cannot order it easily, samples are not collected at scale, or payers are uncertain about downstream cost. Guardant’s 2026 collaboration with Quest Diagnostics is a good example. Shield became available through Quest’s national ordering and collection network, allowing physicians to order through existing Quest accounts and EHR connections while using Quest’s patient service centers and phlebotomy infrastructure.
Another structural shift is that screening tests are creating new pressure on downstream care capacity. Blood-based and stool-based colorectal tests can improve participation, but positive results still require colonoscopy. The FDA notes that Shield is not a replacement for diagnostic colonoscopy, and people with positive results are advised to undergo diagnostic colonoscopy. The FDA also states that Shield detected colorectal cancer 83% of the time in a 7,861-person clinical study, while one out of ten people without advanced abnormal cells may receive a false positive result.
Market Dynamics
Market Drivers
Earlier detection has become a system priority, not only a clinical goal
Screening programs are expanding because healthcare systems want to detect cancers when treatment is more effective and less expensive. The U.S. shift to colorectal screening from age 45 and breast screening from age 40 has expanded the addressable population for screening technologies, primary care outreach, testing logistics, and follow-up pathways.Colorectal cancer screening is becoming a competition between adherence models
The market is no longer only about colonoscopy versus stool testing. It now includes blood-based screening, improved stool DNA tests, at-home collection, pharmacy pickup, EHR ordering, and centralized lab logistics. Exact Sciences’ Cologuard Plus was FDA approved for average-risk adults aged 45 and older, and the company reported 95% colorectal cancer sensitivity, 43% sensitivity for advanced precancerous lesions, and 94% specificity in the BLUE-C study subset.Companion diagnostics are becoming embedded in cancer drug commercialization
Targeted therapies, immunotherapies, antibody-drug conjugates, PARP inhibitors, EGFR inhibitors, ALK inhibitors, RET inhibitors, NTRK inhibitors, HER2-directed therapies, and other biomarker-linked treatments increasingly depend on validated diagnostic confirmation. The FDA defines companion diagnostic devices as IVD or imaging tools that provide information essential for the safe and effective use of a corresponding therapeutic product.MRD is moving from risk monitoring toward treatment decision support
Minimal residual disease testing is becoming more valuable because it can identify molecular recurrence earlier than conventional clinical or radiographic methods in selected contexts. A major 2026 milestone came when Natera announced FDA approval of Signatera CDx as a companion diagnostic for adjuvant atezolizumab in muscle-invasive bladder cancer, describing it as the first companion diagnostic approval in blood-based MRD.Digital pathology is entering regulated precision oncology
AI-supported pathology is shifting from productivity software toward companion diagnostic use. Roche received FDA Breakthrough Device Designation for an AI-driven computational pathology companion diagnostic in non-small cell lung cancer, with the algorithm designed to support more precise patient selection for a TROP2-directed therapy.Market Restraints
Screening tests face higher evidence expectations than treatment-selection tests
Screening is applied to people without symptoms, so false positives, false negatives, overdiagnosis, downstream procedures, and system capacity matter. Multi-cancer early detection tests may become major growth platforms, but broad adoption will depend on evidence showing that they detect clinically meaningful cancers earlier without creating unmanageable diagnostic burden.Reimbursement remains uneven across new diagnostic categories
Established screening categories such as mammography and colorectal screening have clearer payer pathways. Liquid biopsy, MRD, and multi-cancer early detection face more variable coverage, especially when testing is repeated or used outside narrow therapy-selection indications.Operational complexity slows real-world adoption
Precision oncology requires tissue adequacy, sequencing capacity, bioinformatics, variant interpretation, molecular tumor boards, genetic counseling where relevant, payer documentation, and integration into clinical workflows. For health systems, the bottleneck is often not test availability. It is the ability to act on the test result quickly and consistently.Market Segmentation Analysis
By Product and Technology Type
Cancer Screening Tests and Imaging-Based Screening generated USD 18,900 million in 2025, accounting for 36.9% of the market, and are projected to reach USD 38,500 million by 2032. This segment leads because breast, colorectal, cervical, lung, and prostate screening create large recurring testing needs. The strongest near-term opportunities are in patient-friendly formats, organized screening programs, at-home collection, digital reminders, blood-based colorectal screening, and risk-based LDCT lung screening.Molecular and Companion Diagnostics generated USD 13,750 million in 2025, representing 26.8% of the market, and are projected to reach USD 32,900 million by 2032. This segment includes comprehensive genomic profiling, PCR-based mutation testing, immunohistochemistry, fluorescence in situ hybridization, tumor mutational burden, microsatellite instability, homologous recombination deficiency, and approved companion diagnostic assays. Growth is being supported by the increasing number of oncology drugs that require biomarker-based patient selection.
Liquid Biopsy and MRD Testing generated USD 8,620 million in 2025, representing 16.8% of the market, and are projected to reach USD 28,400 million by 2032, making this the fastest-growing product and technology category. The segment benefits from repeatability, tissue-sparing utility, and its ability to capture tumor evolution over time. Its strongest use cases are advanced cancer profiling, resistance monitoring, recurrence risk assessment, and MRD-guided therapy selection.
Digital Pathology and AI-Enabled Diagnostic Platforms generated USD 9,970 million in 2025, representing 19.5% of the market, and are projected to reach USD 17,080 million by 2032. This segment includes whole-slide imaging, AI-assisted pathology interpretation, computational pathology, digital workflow systems, and image-based biomarker analysis. Growth is being supported by pathologist workload pressure, remote review needs, biomarker quantification, and the early move of AI pathology into companion diagnostic applications.
By Cancer Type
Colorectal Cancer generated USD 12,460 million in 2025, representing 24.3% of market revenue, and is projected to reach USD 25,900 million by 2032. This is the largest cancer-type segment because colorectal screening already has multiple reimbursed pathways, including colonoscopy, FIT, stool DNA testing, and now FDA-approved blood-based screening. The key commercial issue is not only test accuracy. It is completion, follow-up colonoscopy access, and patient adherence.Breast Cancer generated USD 10,380 million in 2025, representing 20.3% of market revenue, and is projected to reach USD 22,200 million by 2032. The segment includes mammography, digital breast tomosynthesis, ultrasound and MRI in selected patients, hereditary testing, HER2 testing, HRD testing, PIK3CA testing, ESR1 testing, PD-L1 testing, and liquid biopsy in advanced disease. The 2024 USPSTF recommendation for biennial mammography from age 40 to 74 strengthens the screening base in the U.S. market.
Lung Cancer generated USD 9,620 million in 2025, representing 18.8% of market revenue, and is projected to reach USD 24,600 million by 2032, making it the fastest-growing major cancer type. Lung cancer diagnostics are expanding through low-dose CT screening, broad molecular profiling, liquid biopsy, PD-L1 testing, and emerging computational pathology tools. The USPSTF recommends annual LDCT screening for high-risk adults aged 50 to 80, which supports a recurring screening opportunity in eligible populations.
Prostate Cancer generated USD 7,450 million in 2025, representing 14.5% of market revenue, and is projected to reach USD 15,500 million by 2032. Growth is being supported by PSA-linked diagnostic pathways, reflex biomarkers, MRI-supported evaluation, hereditary risk assessment, BRCA and homologous recombination repair testing, and companion diagnostics in advanced disease.
Other Solid Tumors generated USD 11,330 million in 2025, representing 22.1% of market revenue, and are projected to reach USD 28,680 million by 2032. This segment includes ovarian, pancreatic, gastric, esophageal, liver, bladder, kidney, melanoma, thyroid, endometrial, head and neck, and tumor-agnostic testing. It is strategically important because many of these cancers lack broad standard screening programs, making liquid biopsy, MRD, MCED, and broad genomic profiling commercially attractive.
By End User
Hospitals and Cancer Centers generated USD 22,480 million in 2025, representing 43.9% of market revenue, and are projected to reach USD 48,700 million by 2032. These institutions remain the largest end-user group because they manage imaging, biopsy, pathology, molecular tumor boards, therapy selection, clinical trials, and recurrence monitoring.Diagnostic Laboratories generated USD 15,950 million in 2025, representing 31.1% of market revenue, and are projected to reach USD 39,900 million by 2032. Reference laboratories and molecular testing companies are gaining importance because they can centralize high-throughput testing, bioinformatics, payer operations, at-home sample workflows, and liquid biopsy processing.
Academic and Research Institutions generated USD 6,430 million in 2025, representing 12.5% of market revenue, and are projected to reach USD 12,880 million by 2032. These institutions remain essential for biomarker discovery, validation studies, MCED trials, MRD protocols, AI pathology development, and translational oncology.
Home-Based and Decentralized Testing Channels generated USD 6,380 million in 2025, representing 12.5% of market revenue, and are projected to reach USD 15,400 million by 2032, making this the fastest-growing end-user channel. Growth is being supported by at-home colorectal screening kits, self-sampling, mobile phlebotomy, pharmacy-linked access, EHR-enabled ordering, and national collection partnerships.
Regional Analysis
North America
North America generated USD 25,360 million in 2025, representing 49.5% of global market revenue, and is projected to reach USD 54,200 million by 2032. The region leads because it combines high oncology spending, active screening recommendations, advanced cancer centers, large diagnostic laboratory networks, early liquid biopsy adoption, and strong commercialization pathways for FDA-approved tests.The strongest U.S. market shift is the move from specialist-driven testing to primary-care-accessible screening. Blood-based colorectal screening, stool DNA testing, and decentralized collection models are bringing cancer screening closer to routine preventive care.
USA
The USA generated USD 22,700 million in 2025 and is projected to reach USD 48,600 million by 2032. It remains the most important country market because it has large eligible screening populations, early access to innovative diagnostics, a strong targeted therapy ecosystem, extensive private and public payer structures, and leading companies in liquid biopsy, genomic profiling, MRD, and colorectal screening.The most important U.S. competition will occur around evidence-backed access. Tests with FDA approval, guideline inclusion, payer support, and easy physician ordering will have a stronger position than tests that rely only on technical novelty.
Europe
Europe generated USD 13,450 million in 2025, representing 26.2% of global market revenue, and is projected to reach USD 30,600 million by 2032. Europe is moving toward broader organized screening, but adoption is more evidence-sensitive and payer-disciplined than in the U.S.The Council of the European Union updated its cancer screening recommendation to broaden focus beyond breast, cervical, and colorectal cancer. Member states were encouraged to explore LDCT lung screening, organized prostate screening approaches, and gastric screening strategies in high-incidence regions.
Europe’s under-discussed opportunity is not just new tests. It is quality assurance, data consistency, and implementation design. The EUCanScreen project highlights that breast, cervical, and colorectal screening programs are still incomplete in several member states and aims to support 90% screening offers for eligible citizens while also facilitating lung, prostate, and gastric screening implementation.
Germany
Germany generated USD 3,760 million in 2025 and is projected to reach USD 8,460 million by 2032. Germany is a major opportunity because of its hospital infrastructure, specialist oncology networks, pathology base, and evidence-led reimbursement environment.A key recent development is Germany’s launch of a nationwide lung cancer screening program for people at increased risk. The program uses LDCT and targets individuals aged 50 to 75 with relevant smoking history, with gradual rollout expected because of operational and qualification requirements.
France
France generated USD 2,620 million in 2025 and is projected to reach USD 5,920 million by 2032. France is important because it combines organized screening, public health planning, centralized reimbursement evaluation, and hospital-based oncology infrastructure.France is also modernizing screening access. In 2024, the country simplified invitations and reminders for breast, cervical, and colorectal cancer screening, including dematerialized reminders through personal health accounts and access to colorectal test results by SMS when a phone number is provided.
Asia-Pacific
Asia-Pacific generated USD 12,430 million in 2025, representing 24.3% of global market revenue, and is projected to reach USD 32,080 million by 2032, making it the fastest strategic growth region. Growth is being supported by rising cancer incidence, expanding private healthcare, targeted therapy adoption, screening program expansion, and molecular diagnostics infrastructure in Japan, China, South Korea, Australia, Singapore, and India.Asia-Pacific will not develop as one uniform market. Japan and South Korea are infrastructure-led diagnostic markets. China is volume-led and highly competitive. India and Southeast Asia offer large unmet screening potential but require lower-cost and scalable access models.
Japan
Japan generated USD 3,210 million in 2025 and is projected to reach USD 7,760 million by 2032. Japan is strategically important because of its aging population, advanced hospital system, high diagnostic quality, and structured cancer genomic medicine ecosystem.Japan’s Center for Cancer Genomics and Advanced Therapeutics, or C-CAT, was established to collect genomic and clinical information from cancer genome profiling tests conducted under the national health insurance system. Japan also began national reimbursement of cancer genome profiling tests in 2019, creating a structured base for precision oncology adoption.
China
China generated USD 5,240 million in 2025 and is projected to reach USD 14,850 million by 2032. China is the largest Asia-Pacific opportunity because of population scale, rising cancer burden, hospital modernization, targeted therapy adoption, and a competitive domestic diagnostics industry.China’s screening pathway is expanding through national screening programs that target cervical, breast, colorectal, lung, esophageal, stomach, liver, and nasopharyngeal cancers. The implementation challenge is moving from pilots and selected-area programs to consistent, high-quality population coverage.
South Korea
South Korea generated USD 1,060 million in 2025 and is projected to reach USD 2,720 million by 2032. South Korea is smaller than China and Japan but commercially attractive because of its national screening infrastructure, advanced hospitals, digital health readiness, and rapid adoption of precision oncology when reimbursement is available.South Korea’s National Cancer Screening Program targets six major cancer sites: stomach, liver, colorectum, breast, cervix uteri, and lung, with lung cancer screening introduced in 2019.
Competitive Landscape
The Cancer Screening and Precision Oncology Diagnostics Market is semi-consolidated at the platform level but fragmented by test category. Large diagnostics companies, genomic testing firms, liquid biopsy specialists, pathology platforms, imaging companies, and laboratory networks compete across different parts of the oncology pathway.Competition is shifting from “which test is more sensitive” to “which platform can change clinical behavior.” The winning companies will be those that can prove clinical utility, fit into physician workflows, win payer confidence, provide broad access, and generate results that oncologists can act on.
Four capabilities now define competitive strength:
- Regulatory credibility, especially FDA approval or breakthrough designation in high-impact categories.
- Evidence depth, including prospective trials, guideline inclusion, and clinical utility data.
- Access infrastructure, including EHR ordering, national sample collection, phlebotomy, home testing, and laboratory logistics.
- Decision relevance, meaning the test result changes screening, biopsy, treatment, surveillance, escalation, or de-escalation decisions.
Key Company Profiles
Guardant Health
Guardant Health is one of the most strategically important companies in this market because it operates across liquid biopsy, colorectal cancer screening, comprehensive genomic profiling, and recurrence monitoring. Guardant360 CDx supports solid tumor genomic profiling and companion diagnostic applications, while Shield positions the company in blood-based colorectal cancer screening.Guardant’s 2026 collaboration with Quest Diagnostics is commercially important because it moves blood-based screening into a broad national ordering and collection channel. Quest’s network gives physicians an easier route to order Shield and gives patients more accessible blood draw locations.
Exact Sciences
Exact Sciences remains a leading player in colorectal cancer screening through Cologuard and Cologuard Plus. Cologuard Plus is FDA approved for average-risk adults aged 45 and older and is supported by BLUE-C study data showing 95% colorectal cancer sensitivity, 43% sensitivity for advanced precancerous lesions, and 94% specificity in the reported study subset.The company is also expanding beyond stool-based colorectal screening. In March 2026, Exact Sciences announced AACR presentations covering tumor-informed MRD testing and multi-cancer early detection, including Oncodetect and Cancerguard data.
GRAIL
GRAIL is one of the central companies in multi-cancer early detection through the Galleri test. In January 2026, the company submitted the final module of its FDA PMA application for Galleri, after receiving FDA Breakthrough Device Designation in 2018.In February 2026, GRAIL announced topline results from the NHS-Galleri trial, which evaluated annual multi-cancer screening with Galleri in 142,000 participants aged 50 to 77 in England over three years. This trial matters because MCED adoption will depend on large prospective evidence, stage-shift data, downstream diagnostic burden, and health-system confidence.
Roche and Foundation Medicine
Roche and Foundation Medicine have a strong position in precision oncology diagnostics through tissue-based and liquid comprehensive genomic profiling, companion diagnostics, and digital pathology.Roche’s FDA Breakthrough Device Designation for an AI-driven computational pathology companion diagnostic in non-small cell lung cancer shows how the market is expanding beyond molecular assays into regulated image-based biomarker interpretation.
Natera
Natera is a major MRD company through Signatera. The company’s May 2026 FDA approval of Signatera CDx as a companion diagnostic for adjuvant atezolizumab in muscle-invasive bladder cancer is an important market signal because it validates blood-based MRD as a therapy-selection tool, not only a surveillance tool.Recent Developments
- In May 2026, Natera announced FDA approval of Signatera CDx as a companion diagnostic for adjuvant atezolizumab in muscle-invasive bladder cancer, marking a major milestone for blood-based MRD-guided treatment decisions.
- In March 2026, Guardant Health announced that Shield became accessible through Quest Diagnostics’ national test ordering and collection network, giving physicians nationwide a streamlined route to order the blood-based colorectal screening test.
- In March 2026, Exact Sciences announced new AACR data presentations focused on molecular residual disease testing and multi-cancer early detection, strengthening its position beyond colorectal screening.
- In February 2026, GRAIL announced topline NHS-Galleri trial results from 142,000 participants aged 50 to 77 in England, providing important prospective evidence for the multi-cancer early detection category.
- In January 2026, GRAIL submitted the final PMA module for Galleri to the FDA, an important regulatory step for the MCED market.
Strategic Outlook
The Cancer Screening and Precision Oncology Diagnostics Market is expected to expand steadily through 2032 as cancer care becomes earlier, more molecular, more data-driven, and more longitudinal.Screening will remain the largest revenue base because colorectal, breast, cervical, lung, and prostate screening rely on recurring patient populations. However, the fastest value creation will come from liquid biopsy, MRD, companion diagnostics, AI pathology, and multi-cancer early detection because these technologies directly influence treatment selection, recurrence monitoring, and earlier intervention.
By 2032, the strongest diagnostic companies will not be those with the largest test menu alone. They will be companies that can combine validated performance, regulatory approval, payer confidence, physician adoption, sample collection access, fast turnaround time, clear reporting, and evidence that test results improve clinical decisions.